Back to Search Start Over

The safety and efficacy of dual biological therapy: Dupilumab and fremanezumab.

Authors :
Honigman, Anthony
Oo, Hnin P.
Macdonell, Richard
Kern, Johannes S.
Source :
Australasian Journal of Dermatology. May2024, Vol. 65 Issue 3, pe63-e65. 3p.
Publication Year :
2024

Abstract

This article discusses the safety and efficacy of using dual biological therapy, specifically the combination of dupilumab and fremanezumab, for the treatment of inflammatory cutaneous diseases and migraines. Dupilumab is an interleukin-4/13 receptor alpha antagonist used for conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis. Fremanezumab is a monoclonal antibody used for chronic migraines. The article presents a case study of a patient who successfully received both therapies without adverse events. While there is limited literature on the use of dual biological therapies, this case adds to the evidence suggesting that combining these treatments may be safe and effective. [Extracted from the article]

Details

Language :
English
ISSN :
00048380
Volume :
65
Issue :
3
Database :
Academic Search Index
Journal :
Australasian Journal of Dermatology
Publication Type :
Academic Journal
Accession number :
177321082
Full Text :
https://doi.org/10.1111/ajd.14205